Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTQHO9VM)

DOT Name Engulfment and cell motility protein 3 (ELMO3)
Gene Name ELMO3
Related Disease
Advanced cancer ( )
Colorectal carcinoma ( )
Gastric cancer ( )
Laryngeal carcinoma ( )
Lung cancer ( )
Lung carcinoma ( )
Neoplasm ( )
Non-small-cell lung cancer ( )
Stomach cancer ( )
Head-neck squamous cell carcinoma ( )
UniProt ID
ELMO3_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF11841 ; PF04727 ; PF16457
Sequence
MAPPRNVVKIAIKMRDAIPQLIQLDQAKPLAAVLKEVCDAWSLTHSERYALQFADGHRRY
ITENNRAEIKNGSILCLSTAPDLEAEQLLGGLQSNSPEGRREALRRLVPLASDMIFAREV
ISRNGLQILGTIIEDGDDLGEVLALSLRAFSELMEHGVVSWETLSIPFVRKVVCYVNMNL
MDASVPPLALGLLESVTLSSPALGQLVKSEVPLDRLLVHLQVMNQQLQTKAMALLTALLQ
GASPVERKHMLDYLWQRNLRQFIYKNIIHSAAPMGDEMAHHLYVLQALMLGLLEPRMRTP
LDPYSQEQREQLQVLRQAAFEVEGESSGAGLSADRRRSLCAREFRKLGFSNSNPAQDLER
VPPGLLALDNMLYFSRNAPSAYSRFVLENSSREDKHECPFARGSIQLTVLLCELLRVGEP
CSETAQDFSPMFFGQDQSFHELFCVGIQLLNKTWKEMRATQEDFDKVMQVVREQLARTLA
LKPTSLELFRTKVNALTYGEVLRLRQTERLHQEGTLAPPILELREKLKPELMGLIRQQRL
LRLCEGTLFRKISSRRRQDKLWFCCLSPNHKLLQYGDMEEGASPPTLESLPEQLPVADMR
ALLTGKDCPHVREKGSGKQNKDLYELAFSISYDRGEEEAYLNFIAPSKREFYLWTDGLSA
LLGSPMGSEQTRLDLEQLLTMETKLRLLELENVPIPERPPPVPPPPTNFNFCYDCSIAEP
Function
Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1.
KEGG Pathway
Bacterial invasion of epithelial cells (hsa05100 )

Molecular Interaction Atlas (MIA) of This DOT

10 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Advanced cancer DISAT1Z9 Strong Biomarker [1]
Colorectal carcinoma DIS5PYL0 Strong Biomarker [2]
Gastric cancer DISXGOUK Strong Biomarker [1]
Laryngeal carcinoma DISNHCIV Strong Biomarker [3]
Lung cancer DISCM4YA Strong Altered Expression [4]
Lung carcinoma DISTR26C Strong Altered Expression [4]
Neoplasm DISZKGEW Strong Altered Expression [3]
Non-small-cell lung cancer DIS5Y6R9 Strong Altered Expression [4]
Stomach cancer DISKIJSX Strong Biomarker [1]
Head-neck squamous cell carcinoma DISF7P24 moderate Altered Expression [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Engulfment and cell motility protein 3 (ELMO3). [6]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Engulfment and cell motility protein 3 (ELMO3). [10]
------------------------------------------------------------------------------------
4 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Engulfment and cell motility protein 3 (ELMO3). [7]
Paclitaxel DMLB81S Approved Paclitaxel increases the expression of Engulfment and cell motility protein 3 (ELMO3). [8]
Amiodarone DMUTEX3 Phase 2/3 Trial Amiodarone increases the expression of Engulfment and cell motility protein 3 (ELMO3). [9]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 increases the expression of Engulfment and cell motility protein 3 (ELMO3). [11]
------------------------------------------------------------------------------------

References

1 Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer.Biomed Res Int. 2018 Sep 24;2018:3764032. doi: 10.1155/2018/3764032. eCollection 2018.
2 Knockdown of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer.Int J Mol Sci. 2016 Dec 16;17(12):2119. doi: 10.3390/ijms17122119.
3 ELMO3 predicts poor outcome in T1 laryngeal cancer.Clin Otolaryngol. 2017 Dec;42(6):1181-1186. doi: 10.1111/coa.12845. Epub 2017 Mar 13.
4 Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.Front Oncol. 2019 May 7;9:363. doi: 10.3389/fonc.2019.00363. eCollection 2019.
5 ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report.Cell Oncol (Dordr). 2017 Apr;40(2):193-198. doi: 10.1007/s13402-016-0310-8. Epub 2016 Dec 30.
6 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
7 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
8 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
9 Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
10 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
11 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.